Your browser doesn't support javascript.
loading
Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal.
Meisel, Andreas; Baggi, Fulvio; Behin, Anthony; Evoli, Amelia; Kostera-Pruszczyk, Anna; Mantegazza, Renato; Morales, Raul Juntas; Punga, Anna Rostedt; Sacconi, Sabrina; Schroeter, Michael; Verschuuren, Jan; Crathorne, Louise; Holmes, Kris; Leite, Maria-Isabel.
  • Meisel A; Department of Neurology, Integrated Myasthenia Gravis Center, NeuroCure Clinical Research Center, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Baggi F; Neuroimmunology and Neuromuscular Diseases Unit, Scientific Institute for Research and Health Care Foundation Carlo Besta Neurological Institute, Milan, Italy.
  • Behin A; Department of Neuromyology, Pitié-Salpêtrière Hospital, Public Hospital Network of Paris, Institute of Myology, Paris, France.
  • Evoli A; Catholic University of the Sacred Heart and Agostino Gemelli University Polyclinic Foundation, Scientific Institute for Research and Health Care, Rome, Italy.
  • Kostera-Pruszczyk A; Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
  • Mantegazza R; Neuroimmunology and Neuromuscular Diseases Unit, Scientific Institute for Research and Health Care Foundation Carlo Besta Neurological Institute, Milan, Italy.
  • Morales RJ; Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Punga AR; Department of Medical Science, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden.
  • Sacconi S; Nice University Hospital Center, Nice, France.
  • Schroeter M; Department of Neurology, University Hospital Cologne, Cologne, Germany.
  • Verschuuren J; Neurology, Leiden University Medical Center, Leiden, the Netherlands.
  • Crathorne L; Prescript Communications, Letchworth, UK.
  • Holmes K; Prescript Communications, Letchworth, UK.
  • Leite MI; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Eur J Neurol ; 30(1): 266-282, 2023 01.
Article en En | MEDLINE | ID: mdl-36094738
ABSTRACT
BACKGROUND AND

PURPOSE:

Although myasthenia gravis (MG) is recognized as an immunoglobulin G autoantibody-mediated disease, the relationship between autoantibody levels and disease activity in MG is unclear. We sought to evaluate this landscape through systematically assessing the evidence, testing the impact of predefined variables on any relationship, and augmenting with expert opinion.

METHODS:

In October 2020, a forum of leading clinicians and researchers in neurology from across Europe (Expert Forum for Rare Autoantibodies in Neurology in Myasthenia Gravis) participated in a series of virtual meetings that took place alongside the conduct of a systematic literature review (SLR).

RESULTS:

Forty-two studies were identified meeting inclusion criteria. Of these, 10 reported some correlation between a patient's autoantibody level and disease severity. Generally, decreased autoantibody levels (acetylcholine receptor, muscle-specific kinase, and titin) were positively and significantly correlated with improvements in disease severity (Quantitative Myasthenia Gravis score, Myasthenia Gravis Composite score, Myasthenia Gravis Activities of Daily Living score, Myasthenia Gravis Foundation of America classification). Given the limited evidence, testing the impact of predefined variables was not feasible.

CONCLUSIONS:

This first SLR to assess whether a correlation exists between autoantibody levels and disease activity in patients with MG has indicated a potential positive correlation, which could have clinical implications in guiding treatment decisions. However, in light of the limited and variable evidence, we cannot currently recommend routine clinical use of autoantibody level testing in this context. For now, patient's characteristics, clinical disease course, and laboratory data (e.g., autoantibody status, thymus histology) should inform management, alongside patient-reported outcomes. We highlight the need for future studies to reach more definitive conclusions on this relationship.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Actividades Cotidianas / Miastenia Gravis Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Actividades Cotidianas / Miastenia Gravis Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article